Details der Publikation - Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer (International Federation of Gynecology and Obstetrics Stage III)

Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer (International Federation of Gynecology and Obstetrics Stage III) : first results of a prospective phase 2 study / Nathalie Arians, Meinhard Kieser, Laura Benner, Nathalie Rochet, Sonja Katayama, Florian Sterzing, Klaus Herfarth, Kai Schubert, Lars Schröder, Christina Leitzen, Andreas Schneeweiss, Christof Sohn, Jürgen Debus, and Katja Lindel

PURPOSE: To assess treatment tolerance and toxicity rates of consolidative whole-abdominal radiation therapy (WART) following cytoreductive surgery and carboplatin/paclitaxel chemotherapy in high-risk patients with advanced ovarian cancer (International Federation of Gynecology and Obstetrics stage III) using intensity modulated radiation therapy. METHODS AND MATERIALS: The OVAR-IMRT-02 study is a multicenter, single-arm, phase 2 trial. Twenty patients with optimally debulked ovarian cancer (International Federation of Gynecology and Obstetrics stage III) with complete remission after chemotherapy were treated with intensity modulated WART as a consolidation therapy. A total dose of 30 Gy in 20 fractions of 1.5 Gy was applied to the entire peritoneal cavity. The primary endpoint was treatment tolerability, defined as lack of any Common Terminology Criteria for Adverse Events grade 4 toxicity within 10 weeks after start of treatment; secondary objectives were acute and chronic toxicity, quality of life, rates of therapy disruption and abortion, and progression-free and overall survival. RESULTS: Intensity modulated WART resulted in excellent coverage of the whole peritoneal cavity, with effective sparing of all organs at risk. The primary analysis included all 20 enrolled patients, of whom 19 did not experience Common Terminology Criteria for Adverse Events grade 4 toxicity. Only 1 patient experienced acute grade 4 hematologic toxicity. Thus, the tolerability rate of intensity modulated WART was significantly higher than 70%. No gastrointestinal acute toxicities higher than grade 2 have been observed. During WART, mean global health status decreased by 18.1 points (95% confidence interval 7.1, 29.0). Six weeks after WART, global health status had already increased, with a mean score difference of 4.6 (95% confidence interval -11.1, 20.4) compared with baseline. Similar characteristics were observed for all function scale scores. CONCLUSION: Intensity modulated WART after aggressive surgery and carboplatin/paclitaxel chemotherapy is associated with an acceptable risk of acute toxicity and a treatment tolerability rate significantly higher than 70%. Together with our knowledge about clinical feasibility, meaning excellent coverage of the planning target volume and effective sparing of organs at risk, intensity modulated WART could offer a new therapeutic option for consolidation treatment of patients with advanced ovarian cancer..

Medienart:	E-Artikel

Erscheinungsjahr:	2017
Erschienen:	2017

Enthalten in:	Zur Gesamtaufnahme - volume:99
Enthalten in:	International journal of radiation oncology, biology, physics - 99(2017), 4, Seite 912-920

Sprache:	Englisch

Beteiligte Personen:	Arians, Nathalie, 1986- [VerfasserIn] Kieser, Meinhard [VerfasserIn] Benner, Laura, 1990- [VerfasserIn] Rochet, Nathalie, 1979- [VerfasserIn] Katayama, Sonja [VerfasserIn] Sterzing, Florian, 1979- [VerfasserIn] Herfarth, Klaus [VerfasserIn] Schubert, Kai, 1967- [VerfasserIn] Schneeweiss, Andreas, 1961- [VerfasserIn] Sohn, Christof, 1961- [VerfasserIn] Debus, Jürgen, 1964- [VerfasserIn] Lindel, Katja, 1972- [VerfasserIn]

Links:	Volltext

Themen:	Antineoplastic Combined Chemotherapy Protocols Carboplatin Cisplatin Cytoreduction Surgical Procedures Disease-Free Survival Dose Fractionation Female Humans Middle Aged Ovarian Neoplasms Prospective Studies Quality of Life Radiotherapy, Adjuvant Radiotherapy, Intensity-Modulated

Anmerkungen:	Gesehen am 25.07.2018

Umfang:	9

doi:	10.1016/j.ijrobp.2017.06.2465

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	1577937627

Internformat


LEADER	01000caa a2200265 4500
001	1577937627
003	DE-627
005	20240316100459.0
007	cr uuu---uuuuu
008	180725s2017 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.ijrobp.2017.06.2465 \|2 doi
035			\|a (DE-627)1577937627
035			\|a (DE-576)507937627
035			\|a (DE-599)BSZ507937627
035			\|a (OCoLC)1341014504
040			\|a DE-627 \|b ger \|c DE-627 \|e rda
041			\|a eng
100	1		\|a Arians, Nathalie \|d 1986- \|e verfasserin \|0 (DE-588)1035620782 \|0 (DE-627)74879199X \|0 (DE-576)383388600 \|4 aut
245	1	0	\|a Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer (International Federation of Gynecology and Obstetrics Stage III) \|b first results of a prospective phase 2 study \|c Nathalie Arians, Meinhard Kieser, Laura Benner, Nathalie Rochet, Sonja Katayama, Florian Sterzing, Klaus Herfarth, Kai Schubert, Lars Schröder, Christina Leitzen, Andreas Schneeweiss, Christof Sohn, Jürgen Debus, and Katja Lindel
264		1	\|c 2017
300			\|a 9
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a Gesehen am 25.07.2018
520			\|a PURPOSE: To assess treatment tolerance and toxicity rates of consolidative whole-abdominal radiation therapy (WART) following cytoreductive surgery and carboplatin/paclitaxel chemotherapy in high-risk patients with advanced ovarian cancer (International Federation of Gynecology and Obstetrics stage III) using intensity modulated radiation therapy. METHODS AND MATERIALS: The OVAR-IMRT-02 study is a multicenter, single-arm, phase 2 trial. Twenty patients with optimally debulked ovarian cancer (International Federation of Gynecology and Obstetrics stage III) with complete remission after chemotherapy were treated with intensity modulated WART as a consolidation therapy. A total dose of 30 Gy in 20 fractions of 1.5 Gy was applied to the entire peritoneal cavity. The primary endpoint was treatment tolerability, defined as lack of any Common Terminology Criteria for Adverse Events grade 4 toxicity within 10 weeks after start of treatment; secondary objectives were acute and chronic toxicity, quality of life, rates of therapy disruption and abortion, and progression-free and overall survival. RESULTS: Intensity modulated WART resulted in excellent coverage of the whole peritoneal cavity, with effective sparing of all organs at risk. The primary analysis included all 20 enrolled patients, of whom 19 did not experience Common Terminology Criteria for Adverse Events grade 4 toxicity. Only 1 patient experienced acute grade 4 hematologic toxicity. Thus, the tolerability rate of intensity modulated WART was significantly higher than 70%. No gastrointestinal acute toxicities higher than grade 2 have been observed. During WART, mean global health status decreased by 18.1 points (95% confidence interval 7.1, 29.0). Six weeks after WART, global health status had already increased, with a mean score difference of 4.6 (95% confidence interval -11.1, 20.4) compared with baseline. Similar characteristics were observed for all function scale scores. CONCLUSION: Intensity modulated WART after aggressive surgery and carboplatin/paclitaxel chemotherapy is associated with an acceptable risk of acute toxicity and a treatment tolerability rate significantly higher than 70%. Together with our knowledge about clinical feasibility, meaning excellent coverage of the planning target volume and effective sparing of organs at risk, intensity modulated WART could offer a new therapeutic option for consolidation treatment of patients with advanced ovarian cancer.
650		4	\|a Antineoplastic Combined Chemotherapy Protocols
650		4	\|a Carboplatin
650		4	\|a Cisplatin
650		4	\|a Cytoreduction Surgical Procedures
650		4	\|a Disease-Free Survival
650		4	\|a Dose Fractionation
650		4	\|a Female
650		4	\|a Humans
650		4	\|a Middle Aged
650		4	\|a Ovarian Neoplasms
650		4	\|a Prospective Studies
650		4	\|a Quality of Life
650		4	\|a Radiotherapy, Adjuvant
650		4	\|a Radiotherapy, Intensity-Modulated
700	1		\|a Kieser, Meinhard \|e verfasserin \|0 (DE-588)103276547X \|0 (DE-627)739277766 \|0 (DE-576)168963825 \|4 aut
700	1		\|a Benner, Laura \|d 1990- \|e verfasserin \|0 (DE-588)1155943597 \|0 (DE-627)1018499296 \|0 (DE-576)501946616 \|4 aut
700	1		\|a Rochet, Nathalie \|d 1979- \|e verfasserin \|0 (DE-588)141458593 \|0 (DE-627)703983490 \|0 (DE-576)323678629 \|4 aut
700	1		\|a Katayama, Sonja \|e verfasserin \|0 (DE-588)1067255028 \|0 (DE-627)818554177 \|0 (DE-576)426512979 \|4 aut
700	1		\|a Sterzing, Florian \|d 1979- \|e verfasserin \|0 (DE-588)130141488 \|0 (DE-627)492502722 \|0 (DE-576)298021781 \|4 aut
700	1		\|a Herfarth, Klaus \|e verfasserin \|0 (DE-588)1032757582 \|0 (DE-627)739273116 \|0 (DE-576)171352289 \|4 aut
700	1		\|a Schubert, Kai \|d 1967- \|e verfasserin \|0 (DE-588)1083291157 \|0 (DE-627)847939901 \|0 (DE-576)455687765 \|4 aut
700	1		\|a Schneeweiss, Andreas \|d 1961- \|e verfasserin \|0 (DE-588)109972554 \|0 (DE-627)632849630 \|0 (DE-576)327251859 \|4 aut
700	1		\|a Sohn, Christof \|d 1961- \|e verfasserin \|0 (DE-588)131349287 \|0 (DE-627)507642902 \|0 (DE-576)298422255 \|4 aut
700	1		\|a Debus, Jürgen \|d 1964- \|e verfasserin \|0 (DE-588)1022671421 \|0 (DE-627)717025780 \|0 (DE-576)365774944 \|4 aut
700	1		\|a Lindel, Katja \|d 1972- \|e verfasserin \|0 (DE-588)121342689 \|0 (DE-627)705399176 \|0 (DE-576)292658044 \|4 aut
773	0	8	\|i Enthalten in \|t International journal of radiation oncology, biology, physics \|d Amsterdam [u.a.] : Elsevier Science, 1975 \|g 99(2017), 4, Seite 912-920 \|h Online-Ressource \|w (DE-627)306659662 \|w (DE-600)1500486-7 \|w (DE-576)081986319 \|x 1879-355X \|7 nnns
773	1	8	\|g volume:99 \|g year:2017 \|g number:4 \|g pages:912-920 \|g extent:9
856	4	0	\|u http://dx.doi.org/10.1016/j.ijrobp.2017.06.2465 \|x Verlag \|x Resolving-System \|3 Volltext
912			\|a GBV_USEFLAG_U
912			\|a GBV_ILN_2013
912			\|a ISIL_DE-16-250
912			\|a SYSFLAG_1
912			\|a GBV_KXP
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_60
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2070
912			\|a GBV_ILN_2086
912			\|a GBV_ILN_2098
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2116
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4305
951			\|a AR
952			\|d 99 \|j 2017 \|e 4 \|h 912-920 \|g 9
980			\|2 2013 \|1 01 \|x DE-16-250 \|b 3019504740 \|c 00 \|f --%%-- \|d --%%-- \|e --%%-- \|j --%%-- \|y l01 \|z 25-07-18
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 00 \|s s \|a hd2017
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 01 \|s s \|0 (DE-627)1410508463 \|a wissenschaftlicher Artikel (Zeitschrift)
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 02 \|s s \|a per_14
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 03 \|s s \|a s_6
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s p \|0 (DE-627)1493574302 \|a Arians, Nathalie
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s k \|0 (DE-627)1416741399 \|a Radiologische Universitätsklinik
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s s \|a pos_1
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 05 \|s p \|0 (DE-627)1450272401 \|a Kieser, Meinhard
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 05 \|s k \|0 (DE-627)1416741593 \|a Institut für Medizinische Biometrie und Informatik
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 05 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 05 \|s s \|a pos_2
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 06 \|s p \|0 (DE-627)1571947957 \|a Benner, Laura
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 06 \|s k \|0 (DE-627)1416741593 \|a Institut für Medizinische Biometrie und Informatik
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 06 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 06 \|s s \|a pos_3
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 07 \|s p \|0 (DE-627)1498364535 \|a Rochet, Nathalie
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 07 \|s k \|0 (DE-627)1416822720 \|a Extern
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 07 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 07 \|s s \|a pos_4
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 08 \|s p \|0 (DE-627)1503523462 \|a Katayama, Sonja
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 08 \|s k \|0 (DE-627)1416741399 \|a Radiologische Universitätsklinik
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 08 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 08 \|s s \|a pos_5
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 09 \|s p \|0 (DE-627)1479913677 \|a Sterzing, Florian
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 09 \|s k \|0 (DE-627)1416741399 \|a Radiologische Universitätsklinik
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 09 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 09 \|s s \|a pos_6
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 10 \|s p \|0 (DE-627)145026932X \|a Herfarth, Klaus
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 10 \|s k \|0 (DE-627)1416741399 \|a Radiologische Universitätsklinik
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 10 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 10 \|s s \|a pos_7
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 11 \|s p \|0 (DE-627)1512967920 \|a Schubert, Kai
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 11 \|s k \|0 (DE-627)1416741399 \|a Radiologische Universitätsklinik
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 11 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 11 \|s s \|a pos_8
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 12 \|s p \|0 (DE-627)1436041317 \|a Schneeweiss, Andreas
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 12 \|s k \|0 (DE-627)1416740961 \|a Universitäts-Frauenklinik
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 12 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 12 \|s s \|a pos_11
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 13 \|s p \|0 (DE-627)1436088836 \|a Sohn, Christof
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 13 \|s k \|0 (DE-627)1416740961 \|a Universitäts-Frauenklinik
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 13 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 13 \|s s \|a pos_12
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 14 \|s p \|0 (DE-627)1435777980 \|a Debus, Jürgen
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 14 \|s k \|0 (DE-627)1416741399 \|a Radiologische Universitätsklinik
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 14 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 14 \|s s \|a pos_13
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 16 \|s p \|0 (DE-627)1482869160 \|a Lindel, Katja
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 16 \|s k \|0 (DE-627)1416466967 \|a Medizinische Fakultät Heidelberg
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 16 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 16 \|s s \|a pos_14

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände